The biopharma industry is not taking the threat of even modest civil monetary penalties lightly, as Novartis last week sued the Biden administration’s HHS over plans to assess such penalties for changes that the companies made in regard to a small but high-profile drug discount program for hospitals.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,